/EQRX

EQRX Stock - EQRx, Inc.

Q: What is the analyst price target for EQRX?

Analyst price target information is not currently available for EQRX.

Q: What is EQRX's market cap?

Market capitalization information is not currently available for EQRX.

Healthcare|Biotechnology|NASDAQ

$2.34-2.09%

$0.05 (-2.09%) • Nov 8

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+113.7%upside

Target: $5.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EQRX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.63

52W High$4.75

52W Low$1.58

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A
Operating Income	$-355,877,000	$-196,375,000	$-250,080,000	$-13,878
Net Income	$205.49M	$-90,693,000	$-249,886,000	$-25,524
Net Margin	N/A	N/A	N/A	N/A
EPS	$0.43	$-0.19	$-0.80	$-0.00

Company Overview

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

40%

Hold / Neutral

60%

Sell / Underperform

Analyst Consensus🔴 Bearish

2 Bullish3 Neutral/Bearish

Price Targets

Average Target

↑ 131.8% Upside

Now

Low

Average

High

Based on 4 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 14th 2022	JP Morgan	Downgrade	Underweight	-
November 11th 2022	Goldman	Downgrade	Neutral	$5← $8
November 11th 2022	Jefferies	Downgrade	Hold	$3.2← $5.6
August 16th 2022	JP Morgan	Initiation	Neutral	$5.5
June 13th 2022	Goldman	Initiation	Buy	$8
April 22nd 2022	Cowen	Initiation	Outperform	-

Earnings History & Surprises

EQRX

Beat Rate

57%

Last 7 quarters

Avg Surprise

+7.1%

EPS vs Estimate

Beats / Misses

4/3

Last 12 quarters

Latest EPS

$-0.18

Q4 2023

EPS Surprise History

Q1 22

No data

Q2 22

+32.0%

$-0.17vs$-0.25

Q3 22

+20.0%

$-0.16vs$-0.20

Q4 22

+14.3%

$-0.18vs$-0.21

Q1 23

+73.7%

$-0.05vs$-0.19

Q2 23

-41.7%

$-0.17vs$-0.12

Q3 23

-36.4%

$-0.15vs$-0.11

Q4 23

-12.5%

$-0.18vs$-0.16

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2023	Nov 9, 2023	$-0.16	$-0.18	-12.5%	✗ MISS
Q3 2023	Aug 8, 2023	$-0.11	$-0.15	-36.4%	✗ MISS
Q2 2023	May 8, 2023	$-0.12	$-0.17	-41.7%	✗ MISS
Q1 2023	Feb 23, 2023	$-0.19	$-0.05	+73.7%	✓ BEAT
Q4 2022	Nov 10, 2022	$-0.21	$-0.18	+14.3%	✓ BEAT
Q3 2022	Aug 11, 2022	$-0.20	$-0.16	+20.0%	✓ BEAT
Q2 2022	May 13, 2022	$-0.25	$-0.17	+32.0%	✓ BEAT
Q1 2022	Mar 23, 2022	—	$0.00	—	—
Q3 2021	Sep 30, 2021	—	$-0.08	—	—
Q2 2021	Jun 30, 2021	—	$-0.11	—	—
Q1 2021	Mar 31, 2021	—	$-0.09	—	—
Q4 2020	Dec 31, 2020	—	$-0.57	—	—